Compare Heron Therapeutics Inc (HRTX) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while GraniteShares 2x Long NVDA Daily ETF trades at $36.87 (market cap $3.56B). The key difference: GraniteShares 2x Long NVDA Daily ETF is far larger — about 52.3× Heron Therapeutics Inc's market cap, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| HRTX | NVDL | |
|---|---|---|
Market Cap | $68.01M | $3.56B |
Volume | 1,891,941 | 9,740,643 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $43.02 |
52-Week Low | $0.27 | $21.76 |
Typical Hold Time | 35 Days | 15 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.86, down 6.85% in the last session. Technical indicators show a bullish overall signal with moving averages supporting upward momentum while oscillators remain neutral. Recent news highlights Nvidia's strong Q2 2027 earnings beat and ongoing AI theme strength, though the leveraged ETF has underperformed NVDA's direct returns over the past year.
The outlook remains tied to Nvidia's AI leadership and market performance, with technical support at $36 and resistance at $39. Key risks include leverage decay and NVDA's high valuation, while institutional interest in AI and positive analyst coverage provide potential upside catalysts for the leveraged ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
